Erasca (ERAS) Non-Current Assets (2020 - 2026)
Erasca posted quarterly Non-Current Assets of $207.4 million for Q1 2026, up 32.45% year-on-year from $156.6 million in Q1 2025, and up 88.74% on a QoQ basis from $109.9 million in Q4 2025.
Erasca (ERAS) has 7 years of Non-Current Assets data on file, last reported at $207.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 32.45% year-over-year to $207.4 million; the trailing twelve-month figure through Mar 2026 stood at $572.6 million (down 12.83% YoY), and the FY2025 full-year result was $109.9 million, down 43.26% from the prior year.
- Non-Current Assets for Q1 2026 stood at $207.4 million, up from $109.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $207.4 million in Q1 2026 and bottomed at $63.4 million in Q1 2024.
- The 5-year median for Non-Current Assets is $109.9 million (2025), against an average of $114.9 million.
- The widest annual swing landed in 2022, when Non-Current Assets soared 384.28%; it then slumped 43.26% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $70.4 million in 2022, then climbed by 5.98% to $74.6 million in 2023, then jumped by 159.62% to $193.7 million in 2024, then plunged by 43.26% to $109.9 million in 2025, then surged by 88.74% to $207.4 million in 2026.
- The last three Non-Current Assets figures came in at $207.4 million (Q1 2026), $109.9 million (Q4 2025), and $120.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 207.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.45 Mn |
| Dec 31, 2025 | 109.92 Mn |
| Sep 30, 2025 | 120.48 Mn |
| Jun 30, 2025 | 134.73 Mn |
| Mar 31, 2025 | 156.63 Mn |
| Dec 31, 2024 | 193.73 Mn |
| Sep 30, 2024 | 198.72 Mn |
| Jun 30, 2024 | 107.74 Mn |
| Mar 31, 2024 | 63.40 Mn |
| Dec 31, 2023 | 74.62 Mn |
| Sep 30, 2023 | 113.44 Mn |
| Jun 30, 2023 | 116.81 Mn |
| Mar 31, 2023 | 69.66 Mn |
| Dec 31, 2022 | 70.41 Mn |
| Sep 30, 2022 | 80.68 Mn |
| Jun 30, 2022 | 63.40 Mn |
| Mar 31, 2022 | 72.10 Mn |
| Dec 31, 2021 | 81.40 Mn |
| Sep 30, 2021 | 29.64 Mn |
| Jun 30, 2021 | 13.09 Mn |
| Dec 31, 2020 | 4.84 Mn |